IYR vs XBI
iShares US Real Estate ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.37% for IYR.
- • IYR pays a higher dividend yield (2.39%).
Side-by-side metrics
| Metric | IYR | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.37% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.39% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $4.03B | $10.92B |
YTD return | 11.57% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.92 | 1.01 |
P/E ratio | 26.29 | — |
Last price | $102.52 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
IYR top holdings
| WELL | Welltower Inc | 10.05% |
| PLD | Prologis Inc | 8.75% |
| AMT | American Tower Corp | 4.99% |
| SPG | Simon Property Group Inc | 4.76% |
| EQIX | Equinix Inc | 4.57% |
| DLR | Digital Realty Trust Inc | 4.52% |
| PSA | Public Storage | 4.20% |
| O | Realty Income Corp | 4.14% |
| VMRK | Vivmark Residential | 3.43% |
| VTR | Ventas Inc | 3.34% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About IYR
IYR (iShares US Real Estate ETF) is US real estate companies and REITs. Managed by iShares, the fund carries $4.0B in assets under management, an expense ratio of 0.37%, a dividend yield of 2.39%. Its largest holding is Welltower Inc (WELL), which represents 10.0% of the portfolio. Real Estate is the fund's largest sector exposure at 99.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.